Cardiology

The filing is supported by data from MERIT-1 which showed great improvements in pulmonary vascular resistance and 6-minute walk distance versus ongoing background therapy.

Data from a duo of poster presentations showed icosapent ethyl reduced potentially atherogenic lipid and inflammatory markers in statin-treated patients with reduced kidney function and high triglycerides.

At the 70th Annual AAN 2018 Annual Meeting, Alnylam announced new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hATTR amyloidosis.

A result of cooperation between Amerigen Pharmaceuticals and Dipharma, this is the first approved generic equivalent to Actelion Pharmaceuticals’ version of the drug, Zavesca.

These devices provide additional treatment options for an often-underdiagnosed condition that impacts 12% to 20% of Americans older than 60.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

Data revealed a response rate of 29% for those on the therapy compared to 2% with placebo, with median platelet counts at 24 weeks of 95,000/µL in the SR group, 49,000/µL in the IR group, and 20,500/µL in the non-responders.

SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.

Treatment now offers an individualized approach to control bleeding in appropriate patients undergoing surgery.

The therapy, when used prophylactically either weekly or biweekly, showed a statistically significant reduction in treated bleeds in comparison to no prophylaxis.

In 90 patients that received idarucizumab in the RE-VERSE AD phase 3 trial, the median maximum percentage reversal was 100%.

The therapy, FX1a inhibitor BMS-986177, will advance to phase 2 clinical trials for wider indications.

Mobile apps have a high potential for improving treatment adherence, but rigorous testing is still needed to determine efficacy.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

While pre-pregnancy blood pressure can impact pregnancy outcomes, targeted lifestyle interventions could be utilized to favorably impact reproductive health.

A new meta-analysis helps clear up conflicting trial data and supports what we know about eggs and serum cholesterol.

A 32-year-old man faints shortly after sexual relations with his wife. He is otherwise in good health. What's your ECG read?

This week on MDNN: The SELECT-COMPARE trial reported positive results for upadacitinib, older adults in the US are not being tested for HIV, and the shifting trends in US mortality.

The trial will randomize more than 2500 patients receiving a stent to either OCT-guided or X-ray angiography-guided implantation.

Researchers can agree that medical errors are a big problem in the US. But can they agree on its pathology?

The device is approved for commercial use in more than 50 countries but is limited to investigational use in the United States and Japan.

Sephy Philip, PharmD, discussed the results of the ANCHOR trial, as well as the subgroup analysis.

Steve Deitelzweig, MD, discussed the real-world usage of direct-acting anticoagulants in comparison with the conventional warfarin, as well as the benefits they have shown based on a large data analysis.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

Researchers note that efforts are needed to align clinical practice with clinical guidelines.

The devices have received expanded indication for use in femoral vein closures in addition to previous approval for arterial closures.

Since March 10, almost 100 patients have presented to EDs with vitamin K-dependent coagulopathy, which has been linked to synthetic cannabinoid use.

Physical and social improvements were observed in the 8-month visit, but importantly, were sustained in the 3-year follow-up period.

The decision was made with data from the REDUCE study, which showed a 77% reduction in recurrent ischemic stroke in the patients who underwent PFO closure with the device.

Find out what you know and what you may need to brush up on in the primary and secondary prevention of CVD.